Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.46 +0.08 (+0.60%)
Streaming Delayed Price Updated: 10:52 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Takeda Pharmaceutical Ltd. (NYSE: TAK) Highlighted for Surprising Price Action
Via Investor Brand Network
The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat
Millions of people are scrambling to get their ADHD medication. Here's why. 
Via Investor's Business Daily
Etsy To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Tuesday
B of A Securities cut the price target for Stem, Inc. (NYSE: STEM) from $9 to $5. B of A Securities analyst Julien Dumoulin-Smith downgraded the stock from Neutral to Underperform. Stem shares fell... 
Via Benzinga
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
From Takeda Pharmaceutical Company Limited
Via Business Wire
Zoetis Stock Shows Rising Relative Strength Upgrades
Zoetis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. 
Via Investor's Business Daily
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for. 
Via Investor's Business Daily
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
From Takeda Pharmaceutical Company Limited
Via Business Wire
Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million
HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product... 
Via Talk Markets
Price Growth & Yield: For That Magical Combo, Leave the U.S.
Three foreign stocks, Takeda Pharmaceutical, United Microelectronics, and Coca-Cola FEMSA are showing that magical combination of growth and yield. 
Via MarketBeat
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
Via Benzinga
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) Sets New 52-Week High in Friday Session
Via Investor Brand Network
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
Via Benzinga
Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies
Via Benzinga
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
From HUTCHMED (China) Limited
Via GlobeNewswire
Should You Give Up on Novavax?
After a spectacular 2020 performance, Novavax's shares have plummeted. 
Via The Motley Fool
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
The FDA made a bold move in the CRISPR gene-editing realm. 
Via Investor's Business Daily
2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now
These two high-yield dividend stocks are trading at bargain-basement prices. 
Via The Motley Fool
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
Via Benzinga
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Is This the Telltale Sign to Sell Novavax Stock?
You won't find Novavax's latest bad news trumpeted in a press release. 
Via The Motley Fool
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
From Takeda Pharmaceutical Company Limited
Via Business Wire
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
Via Benzinga
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.